Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.2.1             MARKETS COVERED.. 15
1.2.2             YEARS CONSIDERED FOR THE STUDY
1.3            CURRENCY
1.4            LIMITATIONS
1.5            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.2            SECONDARY DATA
2.2.1             KEY DATA FROM SECONDARY SOURCES
2.3            PRIMARY DATA
2.3.1             KEY DATA FROM PRIMARY SOURCES
2.4            MARKET SIZE ESTIMATION
2.4.1             BOTTOM-UP APPROACH
2.4.2             TOP-DOWN APPROACH. 22
2.5            MARKET BREAKDOWN AND DATA TRIANGULATION
2.6            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            LEUKEMIA THERAPEUTICS: MARKET OVERVIEW.. 29
4.2            LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE & MODE OF
ADMINISTRATION (2019)
4.3            GEOGRAPHICAL SNAPSHOT OF THE LEUKEMIA THERAPEUTICS MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1             DRIVERS
5.2.1.1           RISING PREVALENCE OF LEUKEMIA
5.2.1.1.1           GROWTH IN GERIATRIC POPULATION
5.2.1.1.2           RISING CANCER OCCURRENCE AMONG CHILDREN
5.2.1.2           INTRODUCTION OF INNOVATIVE THERAPIES
5.2.2             RESTRAINTS
5.2.2.1           COMPLEXITIES IN MANUFACTURING
5.2.3             OPPORTUNITIES
5.2.3.1           GROWTH OPPORTUNITIES IN EMERGING ECONOMIES

6.... LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA

6.1            INTRODUCTION
6.2            CHRONIC MYELOID LEUKEMIA
6.2.1             CHRONIC MYELOID LEUKEMIA ACCOUNTS FOR THE LARGEST SHARE OF
THE LEUKEMIA THERAPEUTICS MARKET PRIMARILY DUE TO THE HIGH INCIDENCE OF THIS DISEASE WORLDWIDE
6.3            CHRONIC LYMPHOCYTIC LEUKEMIA
6.3.1             THE INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA INCREASES WITH
AGE AND IS MORE COMMON IN MEN THAN WOMEN
6.4            ACUTE LYMPHOCYTIC LEUKEMIA
6.4.1             ACUTE LYMPHOCYTIC LEUKEMIA MOSTLY AFFECTS CHILDREN BETWEEN
3 AND 7 YEARS OF AGE
6.5            ACUTE MYELOID LEUKEMIA
6.5.1             ACUTE MYELOID LEUKEMIA IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS

7.... LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE

7.1            INTRODUCTION
7.2            TARGETED DRUGS & IMMUNOTHERAPY
7.2.1             TARGETED DRUGS & IMMUNOTHERAPY SEGMENT ACCOUNTS FOR THE LARGER MARKET SHARE DUE TO THE HIGHER EFFICACY & SUCCESS RATE ASSOCIATED WITH THEM AS COMPARED TO CHEMOTHERAPY
7.3            CHEMOTHERAPY
7.3.1             CHEMOTHERAPY IS EFFECTIVE AND ESSENTIAL FOR CANCERS SUCH AS LEUKEMIA THAT HAVE SPREAD THROUGHOUT THE BODY

8.... LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE

8.1            INTRODUCTION
8.2            SMALL MOLECULES
8.2.1             THE SMALL STRUCTURE AND CHEMICAL COMPOSITION OF SMALL MOLECULES HELP THEM TO EASILY PENETRATE CELL MEMBRANES
8.3            BIOLOGICS
8.3.1             THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

9.... LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION

9.1            INTRODUCTION
9.2            ORAL MODE
9.2.1             DRUGS ADMINISTERED ORALLY HAVE LESSER COMPLICATIONS
9.3            INJECTABLE MODE
9.3.1             INJECTABLE MODE OF ADMINISTRATION IS LESS PREFERRED THAN
THE ORAL MODE OF ADMINISTRATION

10.. LEUKEMIA THERAPEUTICS MARKET, BY GENDER

10.1          INTRODUCTION
10.2          MALES
10.2.1           MEN ARE AT HIGHER RISK OF DEVELOPING LEUKEMIA THAN WOMEN
10.3          FEMALES
10.3.1           ACUTE LYMPHOCYTIC LEUKEMIA REMAINS COMMON AMONG WOMEN

11.. LEUKEMIA THERAPEUTICS MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1           US
11.2.1.1         US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET DUE TO THE HIGH PREVALENCE OF LEUKEMIA IN THE COUNTRY
11.2.2           CANADA
11.2.2.1         GOVERNMENT INITIATIVES TO SUPPORT LEUKEMIA RESEARCH AND DEVELOP NOVEL IMMUNOTHERAPIES IS EXPECTED TO SUPPORT THE GROWTH OF THE CANADIAN LEUKEMIA THERAPEUTICS MARKET
11.3          EUROPE
11.3.1           GERMANY
11.3.1.1         GERMANY HAS A STRONG FOUNDATION FOR R&D, INCLUDING OVER 1,000 PUBLIC AND PRIVATE INSTITUTIONS
11.3.2           UK
11.3.2.1         RISING GERIATRIC POPULATION IN THE COUNTRY TO DRIVE MARKET GROWTH AS THE INCIDENCE OF CANCER IS HIGHER IN THE GERIATRIC POPULATION
11.3.3           FRANCE
11.3.3.1         RISING R&D EXPENDITURE IS A MAJOR GROWTH DRIVER IN FRANCE
11.3.4           REST OF EUROPE
11.4          ASIA PACIFIC
11.4.1           JAPAN
11.4.1.1         COMPARATIVELY LENIENT REGULATIONS AND RISING GERIATRIC POPULATION WILL DRIVE MARKET GROWTH
11.4.2           CHINA
11.4.2.1         FAVORABLE INVESTMENTS AND GOVERNMENT SUPPORT WILL CONTRIBUTE TO
THE GROWTH OF THE CHINESE MARKET
11.4.3           INDIA
11.4.3.1         SHORTAGE OF SKILLED PROFESSIONALS MAY RESTRAIN THE GROWTH OF
THE INDIAN MARKET
11.4.4           ROAPAC
11.5          REST OF THE WORLD

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET RANKING ANALYSIS, 2018
12.3          KEY STRATEGIES
12.3.1           REGULATORY APPROVALS/LAUNCHES
12.3.2           ACQUISITIONS
12.3.3           AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
12.4          COMPETITIVE LEADERSHIP MAPPING (2018) 96
12.4.1           VENDOR INCLUSION CRITERIA
12.4.2           VISIONARY LEADERS
12.4.3           INNOVATORS
12.4.4           DYNAMIC DIFFERENTIATORS
12.4.5           EMERGING COMPANIES
12.5          COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
12.5.1           PROGRESSIVE COMPANIES
12.5.2           STARTING BLOCKS
12.5.3           RESPONSIVE COMPANIES
12.5.4           DYNAMIC COMPANIES

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, REGULATORY APPROVALS, AND MNM VIEW)*
13.1          NOVARTIS AG
13.2          ABBVIE
13.3          BRISTOL-MYERS SQUIBB
13.4          F. HOFFMANN-LA ROCHE
13.5          SANOFI
13.6          PFIZER
13.7          AMGEN
13.8          GILEAD SCIENCES
13.9          TAKEDA
13.10        CELGENE
* BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, REGULATORY APPROVALS, AND MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
14.. APPENDIX

LIST OF TABLES

TABLE 1              LEUKEMIA PATIENTS, BY REGION
TABLE 2              ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS IN US
TABLE 3              LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 4              CHRONIC MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 5              CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 6              ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY REGION,
2017–2024 (USD MILLION )
TABLE 7              ACUTE MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 8              LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 9              TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 10            TARGETED DRUGS AND IMMUNOTHERAPY MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 11            TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 12            TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 13            TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 14            TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 15            FEW EXAMPLES OF CHEMOTHERAPY DRUGS
TABLE 16            CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION,
2017–2024 (USD MILLION)
TABLE 17            CHEMOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION)
TABLE 18            CHEMOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 19            CHEMOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 20            CHEMOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION,
2017–2024 (USD MILLION)
TABLE 21            CHEMOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION,
2017–2024 (USD MILLION)
TABLE 22            LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE,
2017–2024 (USD MILLION)
TABLE 23            FEW IMPORTANT SMALL MOLECULES USED TO TREAT DIFFERENT LEUKEMIA TYPE
TABLE 24            LEUKEMIA THERAPEUTICS MARKET FOR SMALL MOLECULES, BY REGION,
2017–2024 (USD MILLION)
TABLE 25            FEW IMPORTANT BIOLOGICS FOR THE TREATMENT OF DIFFERENT LEUKEMIA TYPE
TABLE 26            LEUKEMIA THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION,
2017–2024 (USD MILLION)
TABLE 27            LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION,
2017–2024 (USD MILLION)
TABLE 28            LEUKEMIA THERAPEUTICS MARKET FOR ORAL MODE OF ADMINISTRATION,
BY REGION, 2017–2024 (USD MILLION)
TABLE 29            LEUKEMIA THERAPEUTICS MARKET FOR INJECTABLE MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 30            LEUKEMIA AT A GLANCE (US)
TABLE 31            GLOBAL LEUKEMIA CASES (2018), BY COUNTRY AND GENDER &
FORECAST (2020)
TABLE 32            LEUKEMIA INCIDENCE AND DEATHS, BY GENDER (2018)
TABLE 33            LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
TABLE 34            LEUKEMIA THERAPEUTICS MARKET FOR MALES, BY REGION,
2017–2024 (USD MILLION)
TABLE 35            LEUKEMIA THERAPEUTICS MARKET FOR FEMALES, BY REGION,
2017–2024 (USD MILLION)
TABLE 36            LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 37            NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 38            NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 39            NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION)
TABLE 40            NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 41            US: LEUKEMIA AT A GLANCE
TABLE 42            US: LEUKEMIA, BY TYPE (2017 VS. 2018)
TABLE 43            US: LEUKEMIA NEW CASES & DEATHS, BY STATE (2019)
TABLE 44            US: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 45            US: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 46            US: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 70
TABLE 47            CANADA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 48            CANADA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 49            CANADA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 50            RESEARCH FUNDING: EUROPEAN OVERVIEW
TABLE 51            EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 52            EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 53            EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 54            EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 55            GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 56            GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 57            GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 58            UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATE PER 100,000 POPULATION (ACUTE LYMPHOCYTIC LEUKEMIA)
TABLE 59            UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC LYMPHOCYTIC LEUKEMIA)
TABLE 60            UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (ACUTE MYELOID LEUKEMIA)
TABLE 61            UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC MYELOID LEUKEMIA)
TABLE 62            UK: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 63            UK: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 64            UK: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION)
TABLE 65            FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 66            FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 67            FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 68            ROE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 69            ROE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 70            ROE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 81
TABLE 71            APAC: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 72            APAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 73            APAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 74            APAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 75            JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 76            JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 77            JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 78            CHINA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 79            CHINA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 80            CHINA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 81            INDIA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 82            INDIA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 83            INDIA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 84            ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 85            ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 86            ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 87            ROW: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2017–2024 (USD MILLION)
TABLE 88            ROW: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2017–2024 (USD MILLION)
TABLE 89            ROW: LEUKEMIA THERAPEUTICS MARKET, BY GENDER,
2017–2024 (USD MILLION)
TABLE 90            LEUKEMIA THERAPEUTICS MARKET RANKING BY KEY PLAYER, 2018

 

FIGURE 1            RESEARCH DESIGN
FIGURE 2            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 3            LEUKEMIA THERAPEUTICS MARKET: BOTTOM-UP APPROACH
FIGURE 4            LEUKEMIA THERAPEUTICS MARKET: TOP-DOWN APPROACH
FIGURE 5            DATA TRIANGULATION METHODOLOGY
FIGURE 6            LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 7            LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 8            LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION,
2019 VS. 2024 (USD MILLION)
FIGURE 9            LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 10          LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2019 VS. 2024 (USD MILLION)
FIGURE 11          LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD MILLION)
FIGURE 12          RISING INCIDENCE RATE OF LEUKEMIA TO DRIVE MARKET GROWTH
FIGURE 13          ORAL AND TARGETED DRUGS & IMMUNOTHERAPY SEGMENTS TO DOMINATE
THE MARKET IN 2019
FIGURE 14          US TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 15          LEUKEMIA THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 16          NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET SNAPSHOT
FIGURE 17          KEY DEVELOPMENTS IN THE LEUKEMIA THERAPEUTICS MARKET (2016-2018)
FIGURE 18          MNM DIVE-VENDOR COMPARISON MATRIX: LEUKEMIA THERAPEUTICS MARKET
FIGURE 19          MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS:
LEUKEMIA THERAPEUTICS MARKET
FIGURE 20          NOVARTIS: COMPANY SNAPSHOT (2018)
FIGURE 21          ABBVIE INC.: COMPANY SNAPSHOT (2018)
FIGURE 22          BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2018)
FIGURE 23          F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2018)
FIGURE 24          SANOFI: COMPANY SNAPSHOT (2018)
FIGURE 25          PFIZER: COMPANY SNAPSHOT (2018)
FIGURE 26          AMGEN: COMPANY SNAPSHOT (2018)
FIGURE 27          GILEAD SCIENCES: COMPANY SNAPSHOT (2018)
FIGURE 28          TAKEDA: COMPANY SNAPSHOT (2018)
FIGURE 29          CELGENE: COMPANY SNAPSHOT (2018)

当レポートのプレスリリースは発行されておりません。